The prevalence and natural history of normocalcaemic hypoparathyroidism in a United Kingdom referral population by Schini, M. et al.
This is a repository copy of The prevalence and natural history of normocalcaemic 
hypoparathyroidism in a United Kingdom referral population.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/161001/
Version: Accepted Version
Article:
Schini, M. orcid.org/0000-0003-2204-2095, Stirling, R., Jacques, R. 
orcid.org/0000-0001-6710-5403 et al. (4 more authors) (2020) The prevalence and natural 
history of normocalcaemic hypoparathyroidism in a United Kingdom referral population. 
Clinical Endocrinology. cen.14209. ISSN 0300-0664 
https://doi.org/10.1111/cen.14209
This is the peer reviewed version of the following article: Schini, M., Stirling, R., Jacques, 
R., Oakes, E., Peel, N., Walsh, J. and Eastell, R. (2020), The prevalence and natural 
history of normocalcaemic hypoparathyroidism in a united kingdom referral population. 
Clin Endocrinol., which has been published in final form at 
https://doi.org/10.1111/cen.14209. This article may be used for non-commercial purposes 
in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/cen.14209
 This article is protected by copyright. All rights reserved
THE PREVALENCE AND NATURAL HISTORY OF NORMOCALCAEMIC 
HYPOPARATHYROIDISM IN A UNITED KINGDOM REFERRAL POPULATION
Short title: NHYPO: Prevalence and natural history
Authors: Marian Schini1, Rebecca Stirling1, Richard Jacques2, Eleanor Oakes3, Nicola Peel3, 
Jennifer Walsh1, Richard Eastell1
1Department of Oncology and Metabolism, University of Sheffield, UK
2School of Health and Related Research (ScHARR), University of Sheffield, UK
3Sheffield Teaching Hospitals National Health Service Foundation Trust (STH NHS FT), UK
Acknowledgments: We would like to thank Gemma Minett for providing the information needed 
for the laboratory measurements and Thomas Butterfield for extracting data from the hospitals IT 
storage 
Authors declaration: The authors confirm that the manuscript is original and has not been 
submitted elsewhere. Each author acknowledges that he/she has contributed in a substantial way to 
the work described in the manuscript and its preparation
Funding: MS received funding for her fellowship from the Medical Research Council Centre of 
Excellence for Musculoskeletal Ageing and from Osteoporosis 2000 support group
Data availability statement: The data that support the findings of this study are available from 
the corresponding author upon reasonable request.
Summary
Context: Normocalcaemic hypoparathyroidism (NHYPO) is characterised by persistently low 
levels of parathyroid hormone (PTH) with normal levels of calcium. There is little in current 
literature on this disease, with only two studies published on its prevalence whilst its natural 
history remains relatively unknown. 
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Objectives: to identify the prevalence of NHYPO in a UK referral population and to study the 
natural history of the disorder. 
Design: Retrospective study. Follow up five years
Patients: 6280 patients referred for a BMD measurement in a Metabolic Bone referral centre
Measurements: Prevalence of NHYPO and variability of calcium 
Results: Based on laboratory results on the index day, 22 patients with NHYPO were identified. 
Four patients were excluded due to non-PTH induced hypocalcaemia and unconfirmed data. The 
final prevalence was 0.29%. Only 67% had persistent normocalcaemia, the rest having intermittent 
hypocalcaemia. Two of these patients also had persistently low PTH on two occasions. Most of 
the patients had one PTH measurement available. No patient developed permanent 
hypoparathyroidism. 
Conclusions: The prevalence calculated from this UK referral population is lower when compared 
to results from previous studies. NHYPO patients often have episodes of hypocalcaemia with 
some cases having no apparent reason for calcium levels below the reference range.
Keywords: parathyroid diseases; hypoparathyroidism; hypocalcemia; epidemiology; prevalence; 
calcium metabolism disorders; parathyroid gland; calcium
Introduction
Calcium is an important mineral in the human body; its regulation within tight normal limits is of 
great importance. Parathyroid hormone (PTH) is the main regulator of calcium homeostasis and it 
regulates calcium levels by altering bone resorption, renal calcium excretion and the production of 
1,25(OH)2D 1.  
Endocrine disorders are often characterised by a clinical and a subclinical form, such as 
subclinical hyperthyroidism, characterised by suppressed TSH with normal thyroid hormone 
levels 2. Following a similar pattern, a new phenotype of PHPT has been presented recently in 
literature. Normocalcaemic hyperparathyroidism is a disorder of calcium metabolism which is 
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characterised by persistently normal calcium levels and consistently elevated PTH values after 
other causes of secondary hyperparathyroidism are excluded 3. 
On the other side of the spectrum of calcium related disorders, hypoparathyroidism is a rare 
disorder, characterised by low levels of calcium due to a low PTH secretion. The most common 
cause is acquired hypoparathyroidism, mainly seen after anterior neck surgery. A 
pathophysiological counterpart to normocalcaemic hyperparathyroidism is normocalcaemic 
hypoparathyroidism (NHYPO), which is characterised by normal levels of calcium with persistent 
low levels of parathyroid hormone (PTH). To our knowledge, there is currently no official 
definition for this disorder. There is little in the current literature, with only two studies published 
on its prevalence, whilst its natural history remains relatively unknown 4,5. The prevalence in these 
studies is reported to be 1.1-2.4% at baseline.  Two of these three populations which were quite 
different, [women from five European cities for the Osteoporosis and Ultrasound Study (OPUS) 
and participants of the Dallas Heart Study (DHS), a population-based cohort for the evaluation of 
cardiovascular disease] were then checked six and eight years later (1416 and 2122 patients 
respectively from each study went into follow up) and only 1.1% (out of the original 57 patients, 
35 had blood measurements and only 15 had persistent findings) and 0.09% (out of the 68 patients 
identified, 26 had a follow up and 2 had persistent findings)  respectively were still characterised 
as having NHYPO. None developed hypoparathyroidism. Serum calcium and PTH was only 
checked on two occasions in these studies, so the natural history of serum calcium is unclear. To 
our knowledge, no one has evaluated this before. 
The primary aims of this study were to identify the prevalence of NHYPO and to study the natural 
history of the disorder, hypothesising that individuals presenting as NHYPO may have more labile 
calcium than the general population. A second aim was to compare the variability of adjusted 
calcium between NHYPO patients and a control group from the same cohort. 
Materials and methods
Study population
The work was performed at the Metabolic Bone Centre (MBC) at Sheffield Teaching Hospitals 
National Health Service Foundation Trust (STH NHS FT) in the United Kingdom. Data from 
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patients referred for a bone mineral density (BMD) measurement between the 14th January 2013 to 
the 27th July 2017 were retrospectively evaluated. All the patients included in the analysis had a 
laboratory evaluation including calcium and PTH, performed within 28 days from their scan. In 
this department, a laboratory work-up for secondary osteoporosis is performed in patients having 
any of the following findings: low BMD for age (Z-score<-2), vertebral fracture and/or 
unexplained, accelerated bone loss since a previous scan. The day of the laboratory investigations 
was defined to be the index day. Any other results of calcium and PTH before and after the index 
day were retrieved from the hospitals records and were used to study the natural history of the 
disease. Although biochemical data were available from 2009 onwards, only the data after the 14th 
January 2013 were used, because at that point the laboratory changed the assay for serum calcium, 
and this would probably affect the accuracy of the results. The end of the follow up period was the 
31st July 2018.  
The analysis did not require any ethical approval according to the Sheffield Teaching Hospitals 
Clinical Research Office; it falls under the case note review category. 
Biochemical measurements
Blood was drawn at any point of the day, so patients were not fasting. All the samples were 
analysed in the Chemical Pathology Laboratory, Sheffield Teaching Hospitals NHS Foundation 
Trust.  Serum calcium was measured using a Roche/Hitachi Cobas 8000 e702 automated clinical 
chemistry analyser (Roche Diagnostics GmbH, Mannheim, Germany).  The interassay coefficient 
of variation as measured in the laboratory is 1.1  1.5% at 1.52 mmol/L and 0.6  1.1% at 3.07 
mmol/L. Albumin measurement was performed using a Roche/Hitachi Cobas 8000 e702 analyser. 
The interassay coefficient of variation as measured by the laboratory is 1.5  2.4% at 33.9 g/L and 
1.0  1.7% at 59.7 g/L. The albumin-adjusted calcium was used for this study and was calculated 
using the following equation (as used by the laboratory). The method by which the laboratory 
established its equation was based on a protocol published by Barth et al 6.	 
 =  
 + [0.0172(43  )]
The Pathology Harmony reference range has been in use for adjusted calcium in the UK since 
2011; the range reported is 2.2-2.6 nmol/L (8.8-10.4 mg/dL) 7.
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Intact PTH (second generation) was measured using an immunoassay method by the Roche Cobas 
8000 e602. The interassay coefficient of variation (CV) measured in the laboratory is 2.2  3.2% 
at 34 ng/L, 1.6  1.7% at 94 ng/L and 1.4  1.8% at 839 ng/L, while the reported reference range 
by the manufacturer was 15-65 ng/L (1.6 - 6.9 pmol/L). 
25(OH)D was measured using a competitive binding protein assay and was performed by Roche 
modular analytics Cobas E170. The laboratory interassay coefficient of variation for this assay is 
6.5  9.9% at 48.2 nmol/L and 4.5  6.3% at 92.3 nmol/L.  Patients with a level greater or equal to 
50 nmol/L were considered replete8.
Creatinine was measured using a Roche/Hitachi Cobas c8000 e702 analyser. The interassay 
coefficient of variation for this assay was 2.7  6.1% at 55.7 Mmol/L and 2.3  4.0% at 458 
M!K The equation used to calculate eGFR was the Modification of Diet in Renal Disease 
(MDRD) Study equation. This equation changed in August 2015; the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation has been in use since then 9. A level N>  
ml/min/1.73m2 was considered as normal.
Alkaline phosphatase was measured using a Roche/Hitachi Cobas c8000 e702 analyser. The 
interassay coefficient of variation for this assay was 2.4% at 92.8 IU/L and 1.7% at 224 IU/L. The 
reported reference range was 30-130 IU.  The same analyser was used for the measurement of 
serum phosphate and the interassay coefficient was 1.4% at 1.23 mmol/L and 1.2% at 2.04 
mmol/L. The reported reference range was 0.8-1.5 mmol/L.
Bone mineral density was performed using dual-energy X-ray absorptiometry (DXA) of the 
lumbar spine and the proximal femur in posteroanterior projection. At the time of the study, there 
were three Hologic DXA scanners within the centre. The least significant change (LSC) used in 
the MBC was 4.5% for both the spine and the hip. 
Statistical analysis 
Due to the fact that calcium and PTH are not independent variables, it was considered best to use a 
bivariate statistical approach to define the different categories of patients. Mahalanobis distance 
(MD) is a multi-dimensional generalization of the idea of measuring how many standard 
deviations (SD) away an observation is from the mean of a distribution. Observations are A
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considered outliers if MD2QR22;0.975 =7.378 [97,5th percentile of a chi-squared (X) distribution with 
two degrees of freedom] 10,11. The correlation analysis of adjusted calcium and PTH was 
performed based on a log10 transformation of the two variables.  A similar approach has been 
used in the past to evaluate the prevalence of NHYPO in a different group of patients 4.  Using this 
method, subjects were identified as normal if they were inside the ellipse and abnormal if they 
were outside. Using the laboratory reference intervals for calcium and PTH, patients were divided 
into 10 categories as described below. High or low are referred to values of either adjusted 
calcium or PTH being above or below the reference range respectively. 
To compare the variability of calcium in the two groups, the within-subject standard deviation was 
calculated. The analysis of variance method was used to calculate the within subject variance, as 
this method deals with the case of subjects having different numbers of observations. To follow 
this method, we first checked the assumption that the standard deviation was unrelated to the 
magnitude of the measurement. This was done graphically, by plotting the individual subjects 
standard deviations against their means and analytically by calculating a rank correlation 
coefficient 12. 
The independent samples t-test and the Mann-Whitney test were used to compare quantitative 
data, while chi-square was used for the analysis of categorical data. For the comparison of the 
overall measurements of PTH and adjusted calcium resulting from follow up, we used a mixed 
linear model. Individual variability was modelled using a random effect and the difference 
between groups was estimated using a fixed effect. The statistical analyses have been performed 
using the R studio statistical software version 1.1.442 (RStudio, Inc. Boston).
Definitions of the different groups 
As mentioned in the statistics section, patients were divided into ten categories based on their 
laboratory intervals for adjusted calcium and PTH. The groups of interest for this study were 
defined as follows. Normal: anyone inside the ellipse; Provisional normocalcaemic 
hypoparathyroidism (NHYPO): normal adjusted calcium and low PTH on the index date. 
Hypoparathyroidism: low adjusted calcium and low PTH. In order to characterise these groups 
further, the following procedures were followed. 
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For the NHYPO group, the patients medical notes were reviewed to look for other causes of the 
abnormalities found. Any unconfirmed data were excluded. For the control population, a random 
sample of 300 subjects from inside the ellipse having normal eGFR and being vitamin D replete 
(as defined above) on the index date was chosen. 
Results
In total, 6293 patients attended the Metabolic Bone Centre and were assessed for secondary 
osteoporosis from January 2013 to July 2017. All these patients had a BMD measurement and a 
laboratory evaluation. Thirteen patients did not have PTH available on the index day and were 
excluded. The total number of patients analysed was 6280; their mean age was 66 years and 72% 
were female.  All these patients were given a study ID number starting from S0001 to S6280. 
After applying the Mahalanobis distance, the ellipse seen on Figure 1 was formed by using the 
measurements of PTH and adjusted calcium from the index date (single measurement of each 
variable per patient). In total, 5574 patients were inside the ellipse and were considered as 
normal while the rest were outliers.  Twenty-two patients fulfilled the criteria for NHYPO. The 
evaluation of their medical files excluded four patients. Three patients were excluded due to non-
PTH induced hypercalcaemia; S0051 due to myeloma, while S1743 and S5588 due to metastatic 
cancer. S0756 was excluded because the results extracted by the IT department could not be 
confirmed. 
The group of provisional NHYPO patients consisted of eighteen patients (mean age 45, SD 16.4 
years, 61% female). The prevalence for this population was 0.29% (95% confidence interval 0.18-
0.45%). None of these patients had previous anterior neck surgery or radiation. None of them was 
on active vitamin D. We noted that some patients had other conditions that could affect PTH 
results [thiazides n=1, antiepileptic medications n=4 (both conditions can increase PTH levels); 
one patient had coeliac disease which can cause secondary hyperparathyroidism and thalassaemia 
which can cause functional hypoparathyroidism; four patients were consuming increased levels of 
alcohol).
When studying the natural history, two patterns were identified (Figure 2): persistent 
normocalcaemia (67%) and intermittent hypocalcaemia (28%). One patient only had one 
measurement of calcium during the follow up period (S5738). The minimum, maximum and A
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average values of the adjusted calcium were calculated for each patient, and the graphs of the 
means and the range of values were drawn (Figure 3). There were no statistical differences in 
these two groups in terms of age, gender distribution, average adjusted calcium and PTH levels (p 
>0.05). In three of the patients with intermittent hypocalcaemia, the observed decreases in calcium 
could be explained (the most common cause was vomiting). One patient had one low 
measurement of calcium with no apparent reason explaining the results. Finally, one patient had 
one measurement of low calcium measurements during an epileptic seizure, one linked to low 
vitamin D levels and a third one where no obvious reason for hypocalcaemia was identified. 
When looking at the number of available PTH measurements, eight patients had only one 
measurement of PTH during their follow up. Six patients had two measurements amongst which 
one was low, while one had both measurements below the reference range. Three patients had 
more than two measurements, with two of them having persistently low PTH on two occasions. 
Only one patient from the whole population was found to have hypoparathyroidism. This patient 
had thyroidectomy and developed hypocalcaemia as a result of this. The patient recovered 
spontaneously after a few months.  The control population group consisted of 300 subjects (mean 
age 67, SD 15.6 years, 71% female). The characteristics of the two groups on the index date are 
summarised in Table 1. There were statistically significant differences in the age and BMI of the 
two groups; NHYPO patients were younger and had lower BMI. The gender distribution did not 
differ between the groups. Patients with NHYPO had significantly lower PTH and higher 
phosphate. Alkaline phosphatase and vitamin D levels did not differ between the groups. The 
NHYPO group had lower age and gender adjusted BMD estimates. 
Interestingly, the adjusted calcium on the index date was higher in the control population. 
However, after taking all the follow-up measurements into account, the mean adjusted calcium 
was found to be similar in the NHYPO group compared with the control group (2.34 and 2.35 
mmol/L for NHYPO and control group respectively, p=0.496). The variability of calcium in the 
NHYPO group was significantly higher than the control group [within-subject SD 0.096 (95% CI 
0.085, 0.108) and 0.083 (95% CI 0.080, 0.085) mmol/L respectively). After taking all the follow-
up measurements of PTH into account, the mean PTH was found to be lower in the NHYPO 
compared with the control group (15.8 and 48.0 ng/L respectively, p<0.001).
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Discussion
Normocalcaemic hypoparathyroidism is a disorder characterised by low PTH and normal calcium 
on which limited information is available. To our knowledge, this is the first study of the 
prevalence in a tertiary centre and the also the first study of the natural history of this disease; 
previous studies only showed results from two time-points.  We retrospectively evaluated 6280 
patients attending a referral centre and identified eighteen patients with NHYPO on the index date 
(prevalence 0.29%). Out of them, only 67% had persistent normocalcaemia. The number of PTH 
measurements on these patients were limited, and we could only confirm persistently low PTH in 
one patient. 
The prevalence of NHYPO has been studied previously in the community. Palermo et al studied 
the prevalence in 2419 older (55-79 years old) and 258 younger (30-40 years old) women from 
five European cities for the Osteoporosis and Ultrasound Study (OPUS) and identified 57 subjects 
with NHYPO (prevalence 2.4%), using a similar approach as in our study. In order to get the 
different categories described above, they used the reference range for adjusted calcium, but for 
PTH, they used the geometric mean of the reference range, which probably explains the higher 
baseline prevalence presented in their study 4. We have adjusted this method and brought it closer 
to the everyday clinical practice, by using both the Mahalanobis distance and the reference range 
for both adjusted calcium and PTH.  In the Palermo study, the adjusted calcium at baseline was 
similar to the control population, while PTH was significantly lower in the NHYPO group.  Age, 
BMI and 25(OH)D were similar between the two groups. Six years later, the measurements were 
repeated once in 1416 subjects; only 0.6% of the initial population (1.1% of the ones that went 
into follow up) expressed persistent characteristics of NHYPO 4. Our study showed some 
differences in baseline characteristics, with NHYPO patients being younger, having a lower BMI 
and higher adjusted calcium than the control. The age inclusion criteria in the OPUS study were 
more strict and thus the difference in the results. We only found a higher adjusted calcium at the 
index date. When taking all the repeated measurements into consideration, the levels between 
NHYPO and control were similar. The cohorts differed as OPUS participants were randomly 
selected compared to our cohort in whom there was clinical concern about bone health.
Cusano et al studied two non-referral populations, the Osteoporotic Fractures in Men (MrOS) and 
the Dallas Heart Study (DHS) 5.  MrOS is an unselected community-based study in older men 
aged 65 years or older that had no bilateral hip fractures. Using the baseline values, they identified A
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26 participants (prevalence 1.1%) with NHYPO. They also found lower levels of PTH in the 
NHYPO group when compared to the group having normal PTH. The level of adjusted calcium 
was similar between the groups. They did not find a significant difference in age between the 
groups, unlike our study; however, they only included patients over 65 years. BMI was also 
similar between the groups, while in our study, NHYPO patients were slimmer. BMD results were 
similar 5. Our study found lower Z-scores in the NHYPO population on the index date. One 
explanation for this could be the slightly lower BMI in this group. Another possible explanation 
could be the fact that younger patients are more likely to have causes of secondary osteoporosis 
and thus relatively more affected than the older population investigated. Interestingly, this study 
found significantly higher consumption of calcium supplements N    in the NHYPO group 
(54% versus 23% in the group with normal PTH). The dose of vitamin D supplements was similar 
between the groups 5. This could be the explanation to the fact that the adjusted calcium at 
baseline was slightly higher in the NHYPO group, an observation also seen in our study. 
DHS is a population-based cohort for the evaluation of cardiovascular disease 5. They reported a 
prevalence of 1.9% (68 patients were identified) from the baseline measurements 5. This study 
included a follow up (for 2122 subjects), where a single measurement was performed eight years 
later; out of the 26 subjects with NHYPO that went into follow up, none developed 
hypocalcaemia. Only two had persistent NHYPO (prevalence 0.09% of the population that went 
into follow up). Most of them (20 out of 26) had normal PTH 5.
Normocalcemic hypoparathyroidism was previously characterised as a state of low bone 
turnover, as patients with this disorder were found to have lower bone ALP, collagen type 1 
cross-linked C-telopeptide (CTX) and osteocalcin compared to the normal population but without 
a significant BMD change over time 4. The authors suggested a critical evaluation of potential 
treatment for osteoporosis in these patients, as medications like bisphosphonates can suppress 
bone turnover further and exacerbate adynamic bone disease 4. Moreover, studies with teriparatide 
did not improve BMD in patients with hypoparathyroidism 13. The question of which treatment to 
use in this group of patients becomes more relevant in our study, as all the patients were identified 
during a laboratory investigation for secondary osteoporosis. 
There was a limited number of PTH measurements throughout the patients follow up in our 
study; eight patients out of the eighteen identified as having NHYPO had only one measurement 
available. This suggests that physicians are not so concerned about finding a low level of PTH and A
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they do not tend to follow this up further. However, this disorder could be the subclinical form of 
hypoparathyroidism. Moreover, these patients might be more prone to developing hypocalcaemia 
after they receive medications that can affect calcium levels (eg bisphosphonates, loop diuretics, 
denosumab) or after they develop common symptoms; in our population, three of the NHYPO 
patients had incidence of hypocalcaemia due to vomiting. Interestingly, some episodes of 
hypocalcaemia in our patients could not be explained. Therefore, the low levels could be 
theoretically attributed to the variability of calcium. A concern is that hypocalcaemia can be a 
cause of cardiac arrhythmias and epileptic seizures 14. One of the patients from this population had 
low levels of calcium during an epileptic fit. 
Interestingly, four of our patients were known to have epilepsy and were on treatment with 
antiepileptics which are known to cause an increase in PTH, however, a low level was found 16. 
One patient was on thiazides and one patient had coeliac disease, both known causes of high PTH.  
The patient with coeliac disease also had thalassaemia, so PTH could had been low due to the iron 
load in the parathyroids, a known cause of hypoparathyroidism. Another four patients were 
consuming increased levels of alcohol, which has been reported to decrease the levels of PTH 17. 
Unfortunately, magnesium was not available to check for hypomagnesaemia. 
Further information on this disorder is needed before any official recommendations are made but 
we think that NHYPO should be mentioned in any future guidelines on hypoparathyroidism as it is 
not mentioned in the current ones 18,19; its pathophysiological counterpart, normocalcaemic 
hyperparathyroidism, is already part of international guidelines 20. As mentioned before, there is 
no official definition for NHYPO, but we propose the following definition: normal calcium with 
low PTH should be confirmed on at least two occasions, but normocalcaemia does not have to be 
persistent as long as the average level of calcium is normal; episodes of hypocalcaemia can be part 
of the presentation. As for hypoparathyroidism, we propose that NHYPO includes both idiopathic 
and functional forms of hypoparathyroidism. 
More research should be performed to further characterise this population, ideally a prospective, 
long-term study with repeated measurements of calcium and PTH. The patients identified should 
then be further characterised with more dedicated studies of calcium metabolism. Genetic studies 
would also be of interest. An explanation for this disorder could be that it is a mild form of 
activating CaSR mutation which results in the alteration of the set point for PTH. A mutation on 
the CaSR was reported in patients with normocalcaemic hyperparathyroidism15.A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
This study describes the largest population ever studied to identify provisional NHYPO and 
provides data during a long follow up period (five years). It is the first study that provides data on 
the natural history with adjusted calcium measurements available on more than two timepoints. 
There are several limitations in this study.  The patients studied were identified from a referral 
centre and they were evaluated for causes of secondary osteoporosis, so they might be different 
than the general population. The samples were not fasting, a tourniquet was used to take blood, 
ionised calcium and magnesium were not available and there were not many repeated 
measurements of PTH. The PTH molecule is rapidly degraded and it was difficult to exclude pre-
analytical variations for an inappropriate low PTH level. This was a retrospective observational 
study and the number of measurements varied from patient to patient. The persistence of the 
results could not be always confirmed. The interval between the measurements was not the same, 
as expected in a real-life setting. This limited the possibility of further analyses. The analysis for 
the within-subject SD did not consider the effect of time. Ideally, to give a more accurate estimate 
of the variance, a prospective observational study should be designed, having the same number of 
measurements for each patient at regular intervals. Despite the limitations, this study provided a 
guide to how adjusted calcium varies between the different groups described. 
In summary, we retrospectively evaluated a referral population and found a low prevalence of 
patients with normocalcaemic hypoparathyroidism. The most common pattern was persistent 
normocalcaemia (67%), but there were patients that had intermittent hypocalcaemia. None 
developed persistent hypoparathyroidism.  The clinical implication of this study is that if a patient 
has low PTH but normal serum calcium they should have regular follow-up as they could become 
hypocalcaemic at some point and can have clinical consequences like epilepsy. The findings of 
normal calcium and low PTH have to be confirmed before a certain diagnosis is made. Further 
prospective studies are needed to characterise this group further.
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Tables
Control (n=300) NHYPO (n=18) p value
Female (%) 214 (71) 11 (61) 0.354
Age (years)b 70 (20) 47 (24) <0.001
BMI (g/cm2)c 25.6 (25.0 - 26.3) 22.6 (20.5  24.6) 0.020
PTH (ng/L)c 42.5 (40.8  44.1) 11.1 (10.3 - 11.9) <0.001
Adjusted calcium (mmol/L)a 2.37 (0.08) 2.43 (0.09) 0.006
Phosphate (mmol/L)a 1.12 (0.18) 1.26 (0.18) 0.003
Alkaline phosphatase (IU/L)b 78 (37) 93 (36) 0.059
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25(OH)D (nmol/L)b 78.9 (32.9) 78.3 (61.1) 0.561
Z score spine a -0.2 (1.7) -1.5 (1.2) <0.001
Z score neck a -0.4 (1.0) -1.1 (1.0) 0.011
Table 1: Characteristics of the two groups on the index date; a shown as mean (standard deviation); b shown as median 
(interquartile range); c results from multiple linear regression analysis after adjusting for age, weight and gender. The bold letters 
show the significant differences; BMI: body mass index; PTH: parathyroid hormone; NHYPO: normocalcemic 
hypoparathyroidism. 
Figure legends
Figure 1: Data results from adjusted calcium and PTH. The ellipse was formed using a statistical 
method (Mahalanobis distance) to identify normal subjects (black dots) and abnormal ones 
(red dots). The laboratorys reference range of both adjusted calcium and PTH (horizontal and 
vertical dashed lines respectively), were used to identify patient categories. The shaded area 
includes patients with normocalcaemic hypoparathyroidism (NHYPO). 
Figure 2: The two patterns identified in patients with normocalcaemic hypoparathyroidism when 
studying the natural history of adjusted calcium. Persistent normocalcaemia (left top figure, 
patient S2157) and, intermittent hypocalcaemia (right top figure, patient S0161). The dotted lines 
represent the normal range for adjusted calcium. Both patients were on calcium and vitamin D 
supplements. The bottom graphs represent the variability of parathyroid hormone (PTH). None of 
the two patients maintained low parathyroid hormone throughout their follow up. The increase of 
PTH observed in the patient on the left, could be due to the initiation of zoledronic acid. The 
dotted line represents the lower normal of the reference range for PTH. Adj.Ca: adjusted calcium. 
Figure 3: Means and range of values of different analytes in the 18 NHYPO patients. Out of them, 
only 67% had persistent normocalcaemia (shown in the red arrows). One patient had only one 
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measurement available. The dashed lines represent the reference range for adjusted calcium, 
NHYPO: Normocalcemic hypoparathyroidism
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